Current Round — Janoshik Analytical
Three lots: the MOTS-C 10 mg vial and the two oral tablet SKUs our first partners will carry. Panels were chosen per dosage form — injectables add endotoxin; tablets add potency against label claim.
| Lot / work order | Product | Lab | Panel | Status | Notes | Source |
|---|---|---|---|---|---|---|
WO-0059 |
MOTS-C 10 mg Lyophilized vial |
Janoshik Analytical | HPLC purity + quantity · Endotoxin (LPS, EU/vial) | In progress — awaiting Janoshik report | Flagship injectable SKU. See the MOTS-c compound page. | Get it at LiveWell → |
WO-0025 |
Oral tablet SKU #1 Tablet |
Janoshik Analytical | HPLC purity + quantity (potency vs label) | In progress — awaiting Janoshik report | First tablet SKU for partner intake. Product name added when the lot is registered. | Get it at LiveWell → |
TBD |
Oral tablet SKU #2 Tablet |
Janoshik Analytical | HPLC purity + quantity (potency vs label) | Work order pending | Second tablet SKU for partner intake. Work order pending. | Get it at LiveWell → |
Status is checked live against the public LiveWell lot registry (the same source behind Batch Lookup and /verify). A lot shows "COA published" the moment its independent report is registered.
Where These Lots Come From
Every lot on this page is a LiveWell Peptides production lot (Dallas, TX; cGMP). LiveWell is Path to Peptides' preferred supplier, and the public lot registry behind /verify is LiveWell's own. Each registered lot carries a QR on the vial that resolves to the same record shown here.
How Verification Works
Frequently Asked Questions
Related Tools & Resources